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1. ABSTRACT
Alzheimer disease (AD) is the most common neurodegenerative dementia. It leads to a progressive loss 
of cognitive functions, especially memory. Most of AD cases are sporadic, resulting from the interplay 
of genetic and environmental factors which get involved in the regulation of the expression of 
thousands of genes, a mechanism called epigenetic[1]. Epigenetic modifications, by modifying genes 
transcription, help to orchestrate the phenotypical changes linked to development, aging or even 
diseases and cancer[2]. In AD, recent studies showed rapid, dynamic and persistent epigenetic mutations 
that are believed to have consequences on brain functions. One of the earliest biomarker of AD is 
amyloïd-beta deposition in the brain. According to current studies, deposition of amyloïd-beta begins 
approximately 20 years before the first symptoms linked to the disease, which questions us about what 
could have happened around or before that time. During this study, we tried to identify a possible 
correlation between the experiencing of a strong psychologically stressful life event, which could have 
lead to several epigenetic changes, and the occurrence of Mild Cognitive Impairment (MCI) or AD 
dozens of years later. We also tried to highlight a possible difference in the delay between MCI and AD 
patients.
2. INTRODUCTION
2.1. EPIDEMIOLOGY
Alzheimer Disease (AD) is a neurodegenerative disease and a major cause of dementia in the world, 
with a prevalence of 2% at the age of 60-65 years and over 30-35% in people older than 80 years.[3] It is 
usually diagnosed in people over 65 years old, but in some cases it manifests much earlier.
2.2. PATHO-CLINICAL MANIFESTATIONS
The symptomatology includes inability to acquire new memories, memory loss and cognitive 
impairment, although there are wide differences between people. In the absence of any known etiology 
of the disease and any specific biomarker, the diagnostic of AD is defined by clinical, cognitive and 
functional criteria and can only be definitively confirmed histopathologically with a microscopic 
examination of brain tissue. Criteria for AD were established in July 1984 by the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related 
Disorders Association (commonly referred as NINCDS-ADRDA criteria). Despite being 30 years old, 
these criteria are still in use, with an estimated sensitivity of 81% and specificity of 70%[4]. A recent 
reappraisal of these criteria added morphological morphometric and metabolic imaging and CSF 
specific proteins into the new diagnostic International Working Group (IWG) criteria [5]. It is important 
to notice that these criteria are based on the assumption that AD is a clinical-pathological entity,  
meaning that it is supposed to have a perfect correlation between anatomical modifications and clinical  
manifestations. Today, we know that this isn't the case: a number of cases have shown that before the 
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symptomatic, clinical phase, there is evidence of an asymptomatic, pre-clinical phase of AD[6]. Based 
on these assumptions, a natural progression of the disease can be traced:
1) An asymptomatic pre-clinical phase, characterized by patho-physiological processes alone. The 
progress done since 1984 have allowed to identify these modifications as early as 10-20 years 
before the beginning of the decline of the clinical manifestations (cognitive decline). The main  
modifications most strongly associated with AD are the followings:
- Extracellular S  enile Plaques , due to amyloïd-beta protein (Aβ) aggregation; detectable by 
lumbar puncture and manifesting as a low Aβ42 in Cerebro-Spinal Fluid (CSF) and by a 
positive amyloid imaging at the Proton-Emission Tomography (PET). These are considered to 
be the earliest detectable modifications.
- Signs of Neuronal Degeneration  , mainly intracellular neurofibrillary tangles due to tau 
hyperphosphorylation; detectable by lumbar puncture with an increased total tau and 
phosphorilated tau in CSF. Changes in imaging will follow, such as hypometabolism on the 
Fluoro-Deoxy-Glucose Positron Emission Tomography (FDG-PET) or less sensitively 
hypoperfusion on Single-Proton Emission Computed Tomography (SPECT) in the same regions 
and structural atrophy at specific cortical locations (mesio-temporal, posterior cingulate and 
temporo-parietal associative cortex) with quantified Voxel Based Morphometry (VBM) at the 
Magnetic Resonance Imaging (MRI). These are considered late pathological signs of AD.[7]
CSF Imaging
Less-specific 
biomarkers
Amyloïd-β protein Decreased Aβ42
Positive PET-Amyloïd 
imaging
Neuronal degeneration
Increased 
Tau/Phosphorilated Tau
Hypometabolism (FDG-
PET imaging)
Inflammatory biomarkers 
(cytokines)
Hypoperfusion (SPECT 
imaging)
Oxidative stress 
(isoprostanes)
Structural Atrophy (MRI)
Chart 1: Main AD markers, organized by methodology (upper line) and associated pathological  
modifications (left column).
2) A symptomatic, pre-dementia phase, characteristic of AD, with a clear-cut history of 
worsening of the cognition but without a significant influence on social and professional activities.  
We'll refer to this group of patients as Mild-Cognitive Impairment (MCI) due to AD as amnestic MCI 
were chosen. It usually manifests some years after the pathological modifications, but the precise time-
gap is yet unknown.
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3) A dementia phase, mainly with an amnestic presentation, manifesting as an impairment in 
learning and recall of recently learned information, and at least another deficit between aphasia, 
apraxia, agnosia and perturbation of executive functions. The NINCDS-ADRDA and the revised 
National Institute on Aging/Alzheimer's Association criteria apply to the diagnosis of this phase. It is  
the most advanced stage of the disease and it always leads to the death of the individual.
2.3. GENETICS/EPIGENETICS
Genetics and epigenetics modifications are key factors in outlining two main groups of patients based 
on the age of the beginning of the clinical manifestations:
1. Patients with an early-onset of the disease
These patients develop AD at an early age, usually before turning 50 years old, and they represent a 
small part of the cases (around 5%). Most of these cases are due to one of the 3 autosomal dominant 
mutations in genes identified as responsible for the development of AD: Amyloid Precursor Protein 
(APP) on chromosome 21, Presenilin 1 (PSEN1) on chromosome 14 and Presenilin 2 (PSEN2) on 
chromosome 1[8]. These genes are referred as predictive genes because of their high penetrance of 
nearly 100%.
2. Patients with a late-onset of the disease
These patients develop AD later in life, usually after turning 65 years old with a prevalence doubling 
every 5 years, and are the vast majority (nearly 95%). They rarely present a clearly genetic 
transmission of the disease, whose development is recognized as being mainly due to epigenetic 
factors. Some genetic factors such as mutations in Apolipoprotein E gene (APOE) are recognized to 
play a role in late-onset AD, but they are far less predictable than the mutations presented by the early-
onset patients (APP and PSEN1-2); for example, it has been estimated that population displaying the 
APOE mutation for the disease present an increased risk of 4 times of developing AD compared to 
people with non-mutated APOE. Due to their limited implications in the disease, they are referred as  
susceptibility genes[9].
It appears evident that genetics alone do not fully explain 
the pathogenesis of the disease (APOE mutation being 
mainly a simple risk factor). Epigenetic modifications are 
increasingly recognized as playing a role in the 
progressive cognitive degeneration of patients affected 
with late-onset AD; for example, neprilysin, the gene 
encoding for the main degradation enzyme of Aβ, if 
silenced via methylation, leads to an accumulation of Aβ 
protein, which in turn plays a positive feedback in methylation of the sequence (creating a vicious 
cycle)(Illustration 1)[10].
Whichever external input, being nutrients, infections, smoking or life experiences, can potentially  
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Illustration 1: Vicious cycle of Neprilysin
activate or silence a gene without modifying the genome. Most known epigenetic mechanisms consist 
in methylation of DNA sequences and modifications (methylation, acetylation or phosphorylation) of 
histone proteins. These modifications have been shown to appear years before the clinical 
manifestations and even before the neuropathological changes in dementias, implying that they could 
be implicated in the initiation phase of AD. It is worth noting that epigenetic modifications are  
potentially reversible, meaning that understanding the mechanisms behind these changes may lead to 
the development of an until now nonexistent cure for AD (treatment for AD is, until now, purely 
symptomatic and it consists mainly in Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine 
and Tacrine) and NMDA Receptor Antagonists (Memantine)).
Despite not having yet identified which epigenetic modifications are responsible for it, it has been 
demonstrated that the association between head trauma and APOE mutation leads to a 10 times 
increased risk of developing AD when compared to patient with APOE mutation and no history of head 
trauma. In the late 1990s a study showed that electrical stimulation in mice could reduce Brain Derived 
Neutrophic Factor (BNDF) gene methylation, boosting its activity and consequently promoting new 
synaptic connections; a similar result has been obtained with administration of a DNA-
methyltransferase inhibitor (zebularine), leading to an increase of mRNA levels of BNDF in the 
hyppocampus. In December 2010, a relation between mice with chronic sleep restriction and an 
increase of Aβ-plaques formation in their brains has been demonstrated, while another study managed 
to show how fear stimuli were able to induce epigenetic modifications, going as far as demonstrating 
that said modifications were more important in aged compared to younger mice[11]. All of these 
considerations lead to the speculation that stress inducing events may be implicated in the initiation 
phase of AD. The role of epigenetics has been recently studied in memory processing and suggested to 
play a role in AD.[12-20] We therefore conducted an explorative study of stressful events in the life of 15 
amnesic MCI patients, 15 early AD patients (CDR 0.5-1) and 15 normal controls (NC) and divided 
them into 2 groups, the ones reporting traumatic events more than 30 years before the onset of 
symptoms and the ones reporting traumatic events less than 30 years before the onset of symptoms, 
based on the first preclinical changes recently observed in CSF.
3. METHODOLOGY
3.1. OVERVIEW
The objective of this study consisted in demonstrating a possible implication of old psychologically 
stressful traumatic situations susceptible to cause epigenetic modifications, important enough to lead to  
the development of MCI and AD. To this end, we redacted a detailed questionnaire split into two parts: 
the first one simply consisted in a quick exposure of the argument of the research to the patient and a 
single open question, directly asking if the patient or care-giver would remember any events that she/he 
himself would classify as psychologically traumatic occurred in the past; for simplicity, we arbitrarily 
chose the  30 years before the first symptoms as the line for old and recent traumatic psychological 
stress. In the second part, we gave a detailed list of psychologically traumatic events and asked the 
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patient if such occurrences had happened during his life, also asking to specify when. The list of events 
considered traumatic was as follows:
- Severe accidents (car, work, …) or serious injuries
- Physical violence (aggressions, domestic violence) 
- Sexual harassment
- Death of a close person with a difficult grief
- Divorce or separation, abandonment or infidelity
- Witness of a grave accident or a catastrophe
- Difficult diagnosis (cancer, ...) 
- Important surgery (cardiac, ...) or difficult hospitalization (radio-/chemotherapy, ...)
- Death threats (directly or indirectly)
- Person disappearance
- Major economic problems, bankrupt
- Problems with the law (tribunal, jail, …)
- Job loss, unemployment, mobbing, intimidations
- Separation from own country
- Psychiatric diagnosis/problem (mood disorder, schizophrenia, …)
- Another event not mentioned in here
We ended the questionnaire by asking if the patient has some kind of religious belief and if he wished 
to add something to the matter; then we'd simply take a leave of our interlocutor thanking him for the 
disposability and offering him the possibility to receive a copy of the results. All of these information 
have been collected by the means of telephonic interviews, blind of the diagnosis, that patients and 
normal controls accepted as a complementary personal history that was incomplete or not explored in 
their charts.
Our investigation included a total of 45 patients, classified as it follows depending on their 
characteristics:
1. Patients affected with AD (15 patients)
- Diagnosis of late-onset early AD (over 50-years old at the time of the diagnosis)
- Clinical Dementia Rating (CDR) between 0.5 and 1 (meaning they have been just recently 
diagnosed with these affections)
2. Patients affected with MCI due to AD (15 patients)
- Diagnosis of  amnestic MCI, pure or with executive functions deficit
3. Normal controls (NC) not affected with AD nor MCI (15 patients)
- No diagnosis of MCI or AD
- No other important causes of dementia or other cognitive influencing diseases (schizophrenia...)
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The 30 patients affected by AD and MCI have been selected between 2013 and 2014 from the 
Leenaards Memory Center of the CHUV, Lausanne, Switzerland.
It is worth noting that most of the patients in the AD and MCI groups were still able to fully understand 
and answer our questions. In occasional cases where the answers were of lesser quality by the patient, 
the questionnaire was filled with the help of the care-giver or a family member. The patients have been 
randomized and submitted blindly to us by JG, so that we didn't know the diagnosis until the end of the 
interviews.
3.2 STATISTICAL ANALYSIS
The results have been split into three sections: Total Events Analysis, MMS Analysis and Latency 
Analysis.
 
The results of the Total Events Analysis includes the control cases. Simple calculations were done 
using EXCEL and OPENOFFICE. A Box Plot has been realized as the conclusion of this section.
The rest of the statistics (MMS Analysis and Latency Analysis) has been mostly performed on data 
coming from the two groups of persons having respectively a known MMS score (MCI and AD 
patients) and an established onset of the symptoms, which means that all of the results found in Table 
of Contents 3 and 4 are based on just 30 patients. These results have been analyzed with STATA. 
In every analysis we admitted a statistical result as significant when P was < 0.05 (5%).
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4. RESULTS
4.1. TOTAL EVENTS ANALYSIS
At the beginning, we tried to simply compare the sum of the traumatic events reported by the patients  
affected by AD, the sum of the traumatic events reported by the patients affected by MCI and the sum 
of the traumatic events reported by the NC.
Table of Contents 1: Total events recollected and spontaneously recalled. On the right column, the  
ratio between the spontaneously recalled and the total events recollected.
The results seem to support the hypothesis that traumatic events may be correlated to the development  
of AD/MCI, with patients affected by AD reporting more cases (44), closely followed by the MCI (40) 
and, lastly, the NC (22).
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TOTAL EVENTS [NC/MCI/AD] % [NC/MCI/AD]
All Events 106 [22/40/44]
 → After 1984  → 58 [15/20/23]
 → Before 1984  → 48 [7/20/21]
Spontaneously Recalled 32 [9/12/11] [40%/30%/25%]
 → After 1984  → 17 [6/6/5] [40%/30%/22%]
 → Before 1984  → 15 [3/6/6] [43%/30%/28%]
Severe Accident 3 [1/1/1]
Witness a Catastrophe 5 [2/0/3]
Physical Violence 3 [1/1/1]
Sexual Harassment 2 [1/1/0]
Difficult Grief 41 [8/14/20]
Divorce/Separation/Infidelity 12 [4/4/4]
Severe Diagnosis 7 [2/3/2]
Treatment/Operation/Hospitalization 8 [0/3/5]
Major Economic Problem 2 [0/2/0]
Troubles with the Law 1 [0/1/0]
Job Loss/Unemployment/Mobbing 7 [1/3/3]
Separation from own Country 5 [1/1/2]
Psychiatric Disorder 9 [1/6/2]
Death Threats 0 [0/0/0]
Person Disappearance 0 [0/0/0]
Others not mentioned 1 [0/0/1]
The spontaneously recalled events seem to go more or less in the same direction at first sight, with the 
NC recalling 9 events, the MCI 12 events and the AD 11 events, but when we consider the fact that NC 
patients could remember less events (22) compared to the other two groups, it becomes necessary to 
put them in perspective before analyzing them.
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Graph 1: Comparison between status of patients and traumatic events reported (1) or  
spontaneously recalled (2).
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To do this, we calculated the ratio of spontaneously recalled events on total events reported. The results 
are the following: NC: 40% (9/22), MCI: 30% (12/40), AD: 25% (11/44) and they show an inversion of 
the tendency highlighted with the first results (the more advanced the disease was, the more difficult it  
was for them to spontaneously remember). This seems to suggest that the patients affected by the 
disease have more difficulties to spontaneously remember traumatic events, which may in turn suggest 
that the tendency shown in the reported events could be even more important than what we actually 
found, considering that the reported events were found interviewing the patients. This, however, is a 
mere speculation.
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Graph 2: Spontaneously recalled events on total events reported ratio.
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By analyzing the results with a box-plot, we noticed that the results tend to be non significant.  For a 
powerful study, at least 25 patients in each group would have been necessary, but we chose to do an 
exploratory study with 15 patients in each group. We decided, then, to take a different approach: first, 
we didn't take into consideration anymore the sum of the traumatic events but only the number of 
patients having experienced at least one of them. Then, we conducted two different analysis. Statistics  
have been done on the two groups of patients with MMS scores (the AD and MCI patients).
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Graph 3 (Box Plot): Reported events by status of patients.
4.2. MMS ANALYSIS
Table of Contents 2: Number of patients with spontaneously recalled and with experienced traumatic  
events for groups of patients.
For the MMS Analysis, MCI and AD groups have been put together, so that we could have statistics on 
30 patients (compared to 15 NC). We tried to highlight if the patients who had experienced traumatic 
events had an MMS score lower than those who didn't. For every traumatic event (for example: 
medical operations, death threats,...), a possible difference in the MMS score (dependent variable) 
between the different events (independent variables) has been tested by means of a variance analysis 
(ANOVA). Considering that the MMS score doesn't have a normal distribution, a cubic transformation 
has been applied. The duration of the disease has been chosen as a confounding variable, adjusting the 
MMS scores as if all of the patients had been analyzed with the same time-span of the disease 
(hypothesizing a linear evolution with the time). This allows to easily identify a possible correlation to  
the traumatic events. Considering the small number of patients, no more confounding variables have 
been applied.
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NC MCI AD
70 ± 11 73 ± 12
28
7 (47%) 9 (60%) 8 (53%)
4 (27%) 6 (40%) 4 (27%)
3 (20%) 5 (33%) 5 (33%)
Severe accident [yes] 1 (7%) 1 (7%) 1 (7%)
Physical violence [yes] 1 (7%) 1 (7%) 1 (7%)
Sexual harassment [yes] 1 (7%) 1 (7%) 0 (0%)
Difficult grief [yes] 6 (40%) 10 (67%) 11 (74%)
Divorce/Separation/Infidelity [yes] 4 (27%) 4 (27%) 4 (27%)
Witness a catastrophe [yes] 2 (13%) 0 (0%) 3 (20%)
Severe diagnosis [yes] 2 (13%) 3 (20%) 2 (13%)
Difficult treatment/operation/hospitalization [yes] 0 (0%) 3 (20%) 5 (33%)
Death threats [yes] 0 (0%) 0 (0%) 0 (0%)
Person Disappearance [yes] 0 (0%) 0 (0%) 0 (0%)
Troubles with the law [yes] 0 (0%) 1 (7%) 0 (0%)
Major economic problem [yes] 0 (0%) 2 (13%) 0 (0%)
Job loss/Unemployment/Mobbing [yes] 1 (7%) 3 (20%) 3 (20%)
Separation from own country [yes] 1 (7%) 1 (7%) 2 (13%)
Psychiatric disorder [yes] 1 (7%) 6(40%) 2 (13%)
Others not mentioned [yes] 0 (0%) 0 (0%) 1 (7%)
Answered by the patient him/herself [yes] 15 (100%) 15 (100%) 7 (47%)
Age [years]1 81 ± 93
"Mini Mental State"1 214
Spontaneously recalled traumatic events (all together) [yes]
Spontaneously recalled traumatic events after 1984 [yes]2
Spontaneously recalled traumatic events before 1984 [yes]
1Average (± Standard Deviation)
2Number in the group (over 15) and percentages
3AD significantly different from NC (p<0.05)
4MCI significantly different from AD
Table of Contents 3: Comparison in MMS between MCI and AD patients with and without past  
traumatic events.
At first glance, it would seem that patients who have experienced some traumatic events (like severe 
accident or difficult grief) actually have a lower MMS score compared to those that have not. However, 
the results show, by the means of the descriptive statistics and the ANOVA, that there is no significant 
difference between the groups (P adjusted to the length of the disease). On the contrary, the following 
events have shown significant differences:
1. Physical Violence: people that have reported it show a higher MMS score. Considering the weak 
number of cases (n=2), this result has to be considered cautiously.
2. Psychiatric Disorder: people that have reported it show a higher MMS score (n=8).
This seems to show that patients who have experienced physical violence or psychiatric disorder in the 
past could have some sort of "protection" from developing AD/MCI. It is worth noting that for the 
univariate analysis not adjusted to a confounding variable (P not adj.) there are no differences at all  
between groups.
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NEGATIVE ANSWER POSITIVE ANSWER VALIDITY
MCI + AD MMS MMS MCI + AD P not adj. P adjusted
13 (43%) 17 (57%)
20 (67%) 22.8 ± 6 < 25 ± 3.5 10 (33%) 0.2693 0.8061
20 (67%) 23.5 ± 5 < 23.9 ± 6 10 (33%) 0.6638 0.5934
Severe accident 28 (93%) 23.9 ± 4 > 20 ± 13 2 (7%) 0.6973 0.5621
Physical violence 28 (93%) 23.3 ± 5 < 26.3 ± 4 2 (7%) 0.2325 0.0336
Sexual harassment 29 (97%) 23.6 ± 5 < 24 1 (3%) 0.9010 0.6146
Difficult grief 9 (30%) 24.6 ± 3 > 23.1 ± 6 21 (70%) 0.6152 0.7379
Divorce/Separation/Infidelity 22 (73%) 23.9 ± 4 > 22.9 ± 7 8 (27%) 0.8684 0.4061
Witness a catastrophe 27 (90%) 24.2 ± 4 > 18.3 ± 9 3 (10%) 0.1067 0.2041
Severe diagnosis 25 (83%) 23.5 ± 5 < 24.5 ± 2 5 (17%) 0.9612 0.4617
Difficult treatment/operation/hospitalization 22 (73%) 24.7 ± 3 > 19.3 ± 8 8 (27%) 0.0651 0.2257
Death threats 30 (100%) 23.6 ± 5 / 0 (0%) / /
Person Disappearance 30 (100%) 23.6 ± 5 / 0 (0%) / /
Troubles with the law 29 (97%) 23.4 ± 5 < 28 1 (3%) 0.2647 0.2680
Major economic problem 28 (93%) 23.3 ± 5 < 28.5 ± 1 2 (7%) 0.0556 0.0559
Job loss/Unemployment/Mobbing 24 (80%) 23.5 ± 5 < 24 ± 4 6 (20%) 0.9205 0.3522
Separation from own country 27 (90%) 23.46 ± 5 < 24.5 ± 4 3 (10%) 0.7417 0.1547
Psychiatric disorder 22 (73%) 22.7 ± 5 < 26 ± 3 8 (27%) 0.0696 0.0162
Others not mentioned 29 (97%) 23.5 ± 5 < 24 1 (3%) 0.9946 0.2049
Spontaneously recalled traumatic events (all together)
Spontaneously recalled traumatic events after 1984
Spontaneously recalled traumatic events before 1984
4.3. LATENCY ANALYSIS
For the Latency Analysis, we decided to try and analyze the gathered data following another approach 
by calculating the time between the traumatic events and the onset of the symptomatology, variable that 
we called "Latency". This, of course, applies only to patients who have experienced the events. The 
distribution of this variable being normal, no transformation was needed this time. A variance analysis  
for this variable has been done too, in order to see if the latency was significantly different between the 
two groups of patients.
Table of Contents 4: Latencies between traumatic events and development of MCI/AD.
It seems there is not a real correlations for the "Late Latency" group (< 1984), having more or less the 
same time-span between traumatic events/MCI and traumatic events/AD (the P-value is also extremely 
high). About the "Early Latency" group, however, the results seem to show a shorter latency in patients 
having developed MCI (13 years) compared to those affected by AD (21 years), reinforcing the 
hypothesis of the following sequence:
a) Traumatic event -[13 years]→ b) MCI  -[8 years]→ c) AD
    Traumatic event --------------[21 years]------------→ AD
Despite this, these results too are only a tendency (P > 0.05) and we should've analyzed a bigger group 
of study to obtain more reliable results.
5. DISCUSSION
5.1. OVERVIEW
- Total Events Analysis:
The results obtained from the Total Events Analysis seem to suggest that there is effectively a 
correlation between traumatic events and the development of MCI/AD, considering that the patients  
affected by AD and MCI reported a larger number of traumatic events. The fact that the AD (and to a 
lesser extent the MCI) patients seem to spontaneously remember less traumatic events(compared to the 
NC) leads  to the speculation that the events experienced in their life could actually be more than those  
actually reported, reinforcing the hypothesis. The limited number of patients, however, limits these 
conclusions to mere tendencies.
15
NC MCI AD P
Mean Age 70 ± 11 72.8 ± 11.9 80.9 ± 9.2
Mean Early Latency (>1984) 0.148
Mean Late Latency (<1984) 52.2 ± 16.4 56.5 ± 13.4 0.68
13.8 ± 8.8 21.0 ± 5.3
- MMS Analysis:
The results obtained from the MMS Analysis are compatible with the hypothesis that physical violence 
and psychiatric problems could protect patients from the development of dementia. This seems to point  
towards the opposite direction we were heading for, namely the development of AD following 
epigenetic modifications caused by stressful events. A hypothesis to explain this result can be done, that  
these patients unconsciously developed some kind of "defense" or "resilience" against AD-inducing 
epigenetic modifications, but it is worth noting, though, that there is a certain number of bias that could 
have influenced the result (personal reaction towards stressful events, personal, social or educational 
parameters, Apo E4 phenotype...) that we didn't consider.
- Latency Analysis:
The results obtained from the Latency Analysis show that there may be a correlation between having 
experienced a traumatic event in the last 30 years and developing MCI/AD, going as far as to identify 
the possible latencies between the event and the development of the disease. Despite being just  
tendencies, these results could be used as a basis for further researches in this direction.
5.2 LIMITATIONS OF THE STUDY
We have to acknowledge the limitations of this exploratory study. First of all, the small number of 
patients, purposely chosen as 15 in each group for reasons of time and availability of consenting 
patients. The number of patients that would have given the power of statistic potential significant 
would have been over 25 in each group. Secondly, it is worth noting that it could already be difficult for 
a person not affected by any particular disease to remember events happened more than 10 years in the 
past; this is especially true for patients that, despite being at an early stage of the disease, still suffer of 
a pathology heavily affecting the memory, but stressful events resist more strongly to time in memory. 
The second part of the questionnaire, with itemized questions asking about specific events, was 
designed in order to reduce to minimize the impact of this kind of bias. In the specific case of the two 
seemingly relevant results we have obtained (physical violence and psychiatric problem) it is possible 
that people with a lower MMS score are less likely to remember traumatic events or are less aware of 
being affected with a psychiatric disease, and therefore we questioned the caregiver when the quality of 
answers was suspect of such bias. However, despite knowing the patient very well, the caregiver or 
family member may simply have a different consideration of what the patient may consider a traumatic 
event (for example, a grief may be considered traumatic or not, depending on the way it is accepted). In 
order to further minimize this bias we investigated a little more about the behavior the patient had had 
after the stressful event (for example, in the context of a grief, a patient may have spent months totally 
isolated or have changed his relationships with the members of the family). Despite our efforts, there is 
no possibility to completely exclude this bias. A further limitation is that the patient may simply 
remember an event as traumatic despite not having affected him at all in the past (he may have simply 
elaborated it with the time) or having removed the memory of the trauma as some sort of defense 
despite not having removed the memory of the event. We have not found a way to avoid these last two 
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bias. However, the patients were interviewed blind of any diagnosis (including normal controls), even 
though it was not entirely possible to be perfectly blind based on the quality of the answers or their 
understanding. Another limitation is the time cut-off for old (> 30 years) and recent (< 30 years) stressful 
events, that we chose in order to potentially cover the theoretical changes in CSF that start about 20 years 
before onset of symptoms. Data implementations into statistics may have also been reported with minor 
mistakes. Finally the list of traumatic events we adopted may be incomplete or irrelevant as we do not 
know the cause of the disease, we must therefore acknowledge that the probability of a type I error (false 
positive) is also potentially high due to the considerable number of statistical tests.
This study warrants however further work and additional patients in order to answer the main question, 
since a tendency towards earlier latency between the traumatic event (13 years) for MCI compared to AD 
(21 years) orients towards a possible link between stressful life events and the development of amnestic 
MCI and AD compared to normal controls.
6. CONCLUSION
AD is a very common neurodegenerative disease with a purely symptomatic treatment and of mostly 
unknown etiology. The recent advancements have shown that epigenetic most certainly play a role in 
the pathogenesis of the disease. We tried with this research to highlight a possible relation between 
psychologically traumatic events, a known cause of epigenetic modification, and the onset of the 
disease. Despite not having been able to univocally demonstrate the aforementioned relation, the results  
we were able to collect seem to suggest that a relation of some kind does exist, but further 
investigations are needed to clarify its nature.
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8. ATTACHMENTS
8.1.  QUESTIONNAIRE
Here is a copy of the questionnaire used for the telephonic interviews. Because of the patients residing 
in French-speaking locations, it is done in French language.
Bonjour, mon nom est Fabio Schipani/Sarah El-Achachi, je suis étudiant/e en médecine en 5 e année 
et nous sommes en train de faire un travail de recherche sur la maladie d'Alzheimer avec les Prof. 
Ghika et Démonet de la Consultation Leenards de la mémoire du CHUV, qui ont dû vous informer 
de notre appel et vous envoyer un formulaire d’information et de consentement. On sait à présent 
que les premiers marqueurs de la maladie peuvent se mesurer aussi loin que 15 ans avant le début 
des premiers symptômes, en analysant, par exemple, le liquide céphalo-rachidien à la recherche de 
protéines spécifiques. Pour essayer de rechercher un éventuel facteur déclenchant à ce moment ou 
peu avant, nous recherchons si des événements traumatiques psychologiques graves ou importants 
(séparation, décès, accident…) survenus entre 15-25 ans avant le début des premiers symptômes 
pourraient graver un signal dans le matériel génétique (épigénétique en fait)  qui pourrait  
déclencher la maladie. Nous avons réalisé  un questionnaire rapide afin de voir si on rencontre de 
manière significativement plus souvent ce type de traumatismes psychologiques chez les patients 
atteints d’une maladie d’Alzheimer que chez des gens du même âge non atteints par la maladie ou 
ayant des troubles débutants de la mémoire. Nous voulons aussi analyser si la chronologie 
correspond au début des symptômes. Pour cette raison, nous allons interviewer de façon anonyme 
(nous avons reçu votre téléphone sans le diagnostic) et dans le respect du secret professionnel 
auquel je suis aussi tenu en tant qu’étudiant. En principe la durée de l’interview est de 10 minutes.  
Etes-vous toujours d’accord de répondre à nos questions?
Je vais donc vous poser les questions relatives aux événements traumatiques sur lesquels nous 
sommes en train de focaliser notre recherche.
1. Avez-vous vous même l’impression ou le souvenir d’un (ou plusieurs) traumatisme(s) 
psychologique(s) grave(s) ou important(s) entre 15 et 25 ans en arrière (depuis 1990 environ)? Si 
oui lequel vous semble le plus marquant ou important? Quand a-t-il eu lieu?
2. A présent pour voir s’il y a éventuellement d’autres événements qui vous échapperaient en ce 
moment, je vais vous donner une liste de traumatismes psychologiques possibles et vous me direz si 
vous les avez vécus ces 30 dernières années:
- Un accident grave (voiture, travail…) ou des blessures graves? Si oui quand?
- Des violences physiques (agression, violence familiale) ou agressions sexuelles ? Si oui quand?
- Un décès d’un proche  ou un deuil difficile? Si oui quand?
- Un divorce ou une séparation, un abandon ou une infidélité qui vous a marqué(e) . Si oui quand?
- Etre témoin d’un accident grave ou d’une catastrophe? Si oui quand?
- Une opération ou un diagnostic grave, une hospitalisation (cancer, rayons, chimiothérapie, 
opération cardiaque, TCC ou autre)? Si oui, quand?
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- Une menace de mort (directe ou indirecte). Si oui, quand?
- Une disparition? Si oui, quand?
- Un souci financier grave, une faillite? Si oui, quand?
- Un problème avec la justice (tribunal, emprisonnement…)? Si oui, quand?
- Une perte de travail, chômage, menace professionnelle, mobbing? Si oui, quand?
- Un éloignement à l’étranger? Si oui, quand?
- Un problème psychiatrique (dépression, autre…): Si oui quand?
- Un autre événement que nous n’aurions pas mentionné? Si oui, quand? Souhaiteriez-vous en 
parler brièvement?
Lors de vos épreuves, vous aidez-vous avec une croyance religieuse ou autre?
Avant de terminer, avez-vous des questions ou souhaitez-vous rajouter quelque chose?
Nous sommes arrivés à la fin de notre questionnaire, je vous remercie pour votre collaboration et 
votre disponibilité. Si vous êtes intéressés aux résultats de notre travail, nous vous enverrons un 
résumé lorsqu’il aura été rédigé. Merci et bonne journée/soirée.
8.2. TABLE OF RESULTS [see Attachments 8.2]
8.3.  ABBREVIATIONS
AD: Alzheimer Disease
MCI: Mild Cognitive Impairment
NC: Normal Controls
NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and 
the Alzheimer’s Disease and Related Disorders Association
CDR: Clinical Dementia Rating
MMS: Mini Mental State
Aβ: Beta-Amiloïd protein
CSF: Cerebro-Spinal Fluid
PET: Positron-Emission Tomography
MRI: Magnetic Resonance Imaging
SPECT: Single-Proton Emission Computed Tomography
APP: Amyloid Precursor Protein
PSEN1: Presenilin 1
PSEN2: Presenilin 2
APOE: Apolipoprotein E
BNDF: Brain Derived Neutrophic Factor
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